MERCK KGAA
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
- Conditions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 286
- Registration Number
- NCT01134640
- Locations
- 🇨🇳
Chi Mei Medical Center, Yongkang, Tainan, Taiwan
🇨🇳Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
🇨🇳Buddhist Tzu Chi General Hospital, Taipei, Taiwan
Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 198
- Registration Number
- NCT01128075
- Locations
- 🇨🇦
University of British Columbia, Vancouver, Canada
A Post Marketing Assessment of Gonal f Solution for Injection in a Prefilled Pen for Follicular Stimulation in in Vitro Fertilisation/Embryo Transfer (IVF-ET) Cycles
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 61
- Registration Number
- NCT01125462
- Locations
- 🇷🇸
Dept. for Human Reproduction, Clinical Centre Vojvodina, Novi Sad, Branimira Ćosića 37, Serbia
🇷🇸University hospital for Gynaecology and Obstetrics "Narodni front", Dept. for ART, Belgrade, Kraljice Marije 62, Serbia
🇷🇸Clinical Centre Serbia, Visegradska, Belgrade, Serbia
A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects
- Conditions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 61
- Registration Number
- NCT01125475
- Locations
- 🇳🇴
Sandvika Nevrosenter, Sandvika, Sandviksveien 178, Norway
A Prospective, Observational Study to Assess and Evaluate the Use of Glucophage XR Therapy in the Management of Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 3592
- Registration Number
- NCT01117103
- Locations
- 🇸🇬
Kevin Tan Clinic For Diabetes, Thyroid & Hormones Pte Ltd, Mount Elizabeth, Singapore
A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 76
- Registration Number
- NCT01115725
- Locations
- 🇬🇷
EMBRYOGENESIS IVF Unit, Athens, Kifisias aV, Greece
A Non-interventional Study to Identify the Patients With Severe Luteinizing Hormone Deficiency in the Daily Practice
- Conditions
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 3247
- Registration Number
- NCT01112618
- Locations
- 🇩🇪
Fertility Center Berlin, Spandauer Damm 130, Berlin, Germany
An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period
- Conditions
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 154
- Registration Number
- NCT01112657
- Locations
- 🇨🇳
Kaohsiung Medical University, Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Chang-Gung Memorial Hospital - Linkou Branch, Taoyuan, Taiwan
🇨🇳Chang-Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Taiwan
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
- Conditions
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 133
- Registration Number
- NCT01112345
- Locations
- 🇬🇷
Henry Dunant Hospital - IRB, Athens, Greece
Lutropin Alfa in Women at Risk of Poor Response
- Conditions
- Interventions
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 58
- Registration Number
- NCT01112358
- Locations
- 🇪🇸
Hospital Universitario de La Fe, Valencia, Spain